About this research desk

What this desk is

ForYouPeptides is an independent editorial desk covering the published research on incretin-based metabolic peptides — specifically semaglutide and tirzepatide, two compounds that have accumulated some of the largest randomised-trial datasets in metabolic medicine over the last decade.

This is a reading desk organized like a clinician's briefing: what it is, what was studied, what the data show, what to watch for, what remains unknown. It is not a pharmacy, a clinic, a telehealth service, or a product directory. There are no products sold here, no services offered, and no personal health assessments given.

Every factual claim on this site is sourced to a peer-reviewed study or authoritative clinical reference — and cited by number. The references list at /references is the complete source inventory. Citations are linked to PubMed or the issuing publisher where possible. Where a finding applies to a specific species, trial population, or dose, we say so explicitly.

Editorial method

The literature on semaglutide and tirzepatide is large, growing rapidly, and predominantly sponsor-funded (manufacturer-run phase 3 trials are the primary evidence base for both). This desk tries to present that evidence clearly, including both the strength of the evidence and its limitations.

Selection criteria: priority is given to phase 3 randomised controlled trials, peer-reviewed meta-analyses, and dedicated safety reviews published in indexed journals (primarily the New England Journal of Medicine and Frontiers in Endocrinology for this desk). Mechanism-of-action studies in animal models are included when they document the biological basis for trial-observed effects. Clinical-reference chapters (StatPearls) are used for established regulatory and mechanistic facts.

Attribution discipline: every numerical finding is attributed to its source trial and population. A weight-loss percentage from a trial in adults with obesity is not extrapolated to type 2 diabetes populations, and vice versa. Head-to-head trial data are clearly labelled as such.

What we report on cautions: safety signals — gallbladder disease, lean-mass loss, thyroid concerns, retinopathy risk — are reported alongside efficacy data, not in footnotes. Known class warnings are disclosed regardless of whether they apply to both compounds or one.

Community reports: for each compound, a section covers effects described by people using these agents in research or clinical contexts. These are clearly labeled as anecdotal, not clinical evidence, sourced from patient-review aggregators and published interview studies, and never used to make efficacy or dosing claims.

Independence and disclaimer

ForYouPeptides has no affiliation with any pharmaceutical manufacturer, compounding pharmacy, telehealth platform, or weight-loss clinic. It does not sell, recommend, or source any compound. It does not accept advertising or sponsored content.

The content on this site is editorial commentary on publicly available research. It is not medical advice, not a treatment recommendation, and not a substitute for consultation with a qualified clinician. The compounds covered here are FDA-approved prescription medicines; their use, prescribing, and dispensing are regulated activities outside the scope of this desk.

All research findings are reported as published. Readers should consult current prescribing information and peer-reviewed literature directly for clinical decision-making.